Genetic risk factors for type 2 diabetes with pharmacologic intervention in African-American patients with schizophrenia or schizoaffective disorder

Schizophrenia Research

Volumn 114, Issue 1-3, 2009, Pages 50-56

  Irvin, M R ^a   Wiener, H W ^a   Perry, R P ^a   Savage, R M ^b   Go, R C P ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Antipsychotics; CAPN10; ENPP1; TCF7L2

Indexed keywords

ADENINE; CALPAIN 10; ECTOENZYME NUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 2; GUANINE; MOOD STABILIZER; NEUROLEPTIC AGENT; PHOSPHODIESTERASE; TRANSCRIPTION FACTOR 7 LIKE 2; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; ALLELE; ARTICLE; FEMALE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOGENETICS; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AFRICAN AMERICANS; AGED; ANTIPSYCHOTIC AGENTS; CALPAIN; DIABETES MELLITUS, TYPE 2; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETICS, POPULATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PHARMACOGENETICS; PHOSPHORIC DIESTER HYDROLASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHOTIC DISORDERS; PYROPHOSPHATASES; RISK FACTORS; SCHIZOPHRENIA; TCF TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR 7-LIKE 2 PROTEIN;

EID: 69849107379     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2009.07.008     Document Type: Article

References (68)

1. Abate N., Carulli L., Cabo-Chan Jr. A., Chandalia M., Snell P.G., and Grundy S.M. Genetic polymorphism PC-1 K121Q and ethnic susceptibility to insulin resistance. J. Clin. Endocrinol. Metab. 88 (2003) 5927-5934
2. Alimohamad H., Sutton L., Mouyal J., Rajakumar N., and Rushlow W.J. The effects of antipsychotics on beta-catenin, glycogen synthase kinase-3 and dishevelled in the ventral midbrain of rats. J. Neurochem. 95 (2005) 513-525
3. Aliyu M.H., Calkins M.E., Swanson Jr. C.L., Lyons P.D., Savage R.M., May R., Wiener H., McLeod-Bryant S., Nimgaonkar V.L., Ragland J.D., Gur R.E., Gur R.C., Bradford L.D., Edwards N., Kwentus J., McEvoy J.P., Santos A.B., McCleod-Bryant S., Tennison C., Go R.C., and Allen T.B. Project among African-Americans to explore risks for schizophrenia (PAARTNERS): recruitment and assessment methods. Schizophr. Res. 87 (2006) 32-44
4. Allison D.B., and Casey D.E. Antipsychotic-induced weight gain: a review of the literature. J. Clin. Psychiatry 62 Suppl 7 (2001) 22-31
5. Ananth J., Venkatesh R., Burgoyne K., and Gunatilake S. Atypical antipsychotic drug use and diabetes. Psychother. Psychosom. 71 (2002) 244-254
6. Ananth J., Parameswaran S., and Gunatilake S. Side effects of atypical antipsychotic drugs. Curr. Pharm. Des. 10 (2004) 2219-2229
7. Arranz B., Rosel P., Ramirez N., Duenas R., Fernandez P., Sanchez J.M., Navarro M.A., and San L. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J. Clin. Psychiatry 65 (2004) 1335-1342
8. Bellivier F. Schizophrenia, antipsychotics and diabetes: genetic aspects. Eur. Psychiatr. 20 Suppl 4 (2005) S335-S339
9. Bowden C.L., and Singh V. Valproate in bipolar disorder: 2000 onwards. Acta Psychiatr. Scand. Suppl. (2005) 13-20
10. Bozkurt O., de Boer A., Grobbee D.E., de Leeuw P.W., Kroon A.A., Schiffers P., and Klungel O.H. Variation in renin-angiotensin system and salt-sensitivity genes and the risk of diabetes mellitus associated with the use of thiazide diuretics. Am. J. Hypertens. 22 (2009) 545-551
11. Chandalia M., Grundy S.M., Adams-Huet B., and Abate N. Ethnic differences in the frequency of ENPP1/PC1 121Q genetic variant in the Dallas Heart Study cohort. J. Diabetes Complicat. 21 (2007) 143-148
12. Costanzo B.V., Trischitta V., Di Paola R., Spampinato D., Pizzuti A., Vigneri R., and Frittitta L. The Q allele variant (GLN121) of membrane glycoprotein PC-1 interacts with the insulin receptor and inhibits insulin signaling more effectively than the common K allele variant (LYS121). Diabetes 50 (2001) 831-836
13. de Leon J., and Diaz F.J. Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: the clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reasonable strategy. Schizophr. Res. 96 (2007) 185-197
14. DeLisi L.E., Shaw S.H., Crow T.J., Shields G., Smith A.B., Larach V.W., Wellman N., Loftus J., Nanthakumar B., Razi K., Stewart J., Comazzi M., Vita A., Heffner T., and Sherrington R. A genome-wide scan for linkage to chromosomal regions in 382 sibling pairs with schizophrenia or schizoaffective disorder. Am. J. Psychiatry 159 (2002) 803-812
15. Dinesen H., Gram L., Andersen T., and Dam M. Weight gain during treatment with valproate. Acta Neurol. Scand. 70 (1984) 65-69
16. Dong H., Maddux B.A., Altomonte J., Meseck M., Accili D., Terkeltaub R., Johnson K., Youngren J.F., and Goldfine I.D. Increased hepatic levels of the insulin receptor inhibitor, PC-1/NPP1, induce insulin resistance and glucose intolerance. Diabetes 54 (2005) 367-372
17. Ewens W.J., and Spielman R.S. The transmission/disequilibrium test: history, subdivision, and admixture. Am. J. Hum. Genet. 57 (1995) 455-464
18. Florez J.C., Jablonski K.A., Bayley N., Pollin T.I., de Bakker P.I., Shuldiner A.R., Knowler W.C., Nathan D.M., and Altshuler D. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N. Engl. J. Med. 355 (2006) 241-250
19. Galceran J., Farinas I., Depew M.J., Clevers H., and Grosschedl R. Wnt3a-/-like phenotype and limb deficiency in Lef1(-/-)Tcf1(-/-) mice. Genes Dev. 13 (1999) 709-717
20. Garant M.J., Kao W.H., Brancati F., Coresh J., Rami T.M., Hanis C.L., Boerwinkle E., and Shuldiner A.R. SNP43 of CAPN10 and the risk of type 2 diabetes in African-Americans: the atherosclerosis risk in communities study. Diabetes 51 (2002) 231-237
21. Gianfrancesco F.D., Grogg A.L., Mahmoud R.A., Wang R.H., and Nasrallah H.A. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J. Clin. Psychiatry 63 (2002) 920-930
22. Gonzalez-Sanchez J.L., Martinez-Larrad M.T., Fernandez-Perez C., Kubaszek A., Laakso M., and Serrano-Rios M. K121Q PC-1 gene polymorphism is not associated with insulin resistance in a Spanish population. Obes. Res. 11 (2003) 603-605
23. Groleger U. Off-label use of antipsychotics: rethinking "off-label". Psychiatr. Danub. 19 (2007) 350-353
24. Groves C.J., Zeggini E., Minton J., Frayling T.M., Weedon M.N., Rayner N.W., Hitman G.A., Walker M., Wiltshire S., Hattersley A.T., and McCarthy M.I. Association analysis of 6, 736 U.K. subjects provides replication and confirms TCF7L2 as a type 2 diabetes susceptibility gene with a substantial effect on individual risk. Diabetes 55 (2006) 2640-2644
25. Gu H.F., Almgren P., Lindholm E., Frittitta L., Pizzuti A., Trischitta V., and Groop L.C. Association between the human glycoprotein PC-1 gene and elevated glucose and insulin levels in a paired-sibling analysis. Diabetes 49 (2000) 1601-1603
26. Harris F., Biswas S., Singh J., Dennison S., and Phoenix D.A. Calpains and their multiple roles in diabetes mellitus. Ann. N. Y. Acad Sci. 1084 (2006) 452-480
27. Helgason A., Palsson S., Thorleifsson G., Grant S.F., Emilsson V., Gunnarsdottir S., Adeyemo A., Chen Y., Chen G., Reynisdottir I., Benediktsson R., Hinney A., Hansen T., Andersen G., Borch-Johnsen K., Jorgensen T., Schafer H., Faruque M., Doumatey A., Zhou J., Wilensky R.L., Reilly M.P., Rader D.J., Bagger Y., Christiansen C., Sigurdsson G., Hebebrand J., Pedersen O., Thorsteinsdottir U., Gulcher J.R., Kong A., Rotimi C., and Stefansson K. Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat. Genet. 39 (2007) 218-225
28. Howes O.D., Bhatnagar A., Gaughran F.P., Amiel S.A., Murray R.M., and Pilowsky L.S. A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. Am. J. Psychiatry 161 (2004) 361-363
29. Jarrett R.J. Epidemiology and public health aspects of non-insulin-dependent diabetes mellitus. Epidemiol. Rev. 11 (1989) 151-171
30. Kang U.G., Seo M.S., Roh M.S., Kim Y., Yoon S.C., and Kim Y.S. The effects of clozapine on the GSK-3-mediated signaling pathway. FEBS Lett. 560 (2004) 115-119
31. Kapur S., and Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol. Psychiatry 50 (2001) 873-883
32. Keene K.L., Mychaleckyj J.C., Smith S.G., Leak T.S., Perlegas P.S., Langefeld C.D., Freedman B.I., Rich S.S., Bowden D.W., and Sale M.M. Association of the distal region of the ectonucleotide pyrophosphatase/phosphodiesterase 1 gene with type 2 diabetes in an African-American population enriched for nephropathy. Diabetes 57 (2008) 1057-1062
33. Ketter T.A., Nasrallah H.A., and Fagiolini A. Mood stabilizers and atypical antipsychotics: bimodal treatments for bipolar disorder. Psychopharmacol. Bull. 39 (2006) 120-146
34. Kubaszek A., Pihlajamaki J., Karhapaa P., Vauhkonen I., and Laakso M. The K121Q polymorphism of the PC-1 gene is associated with insulin resistance but not with dyslipidemia. Diabetes Care. 26 (2003) 464-467
35. Lewis J.P., Palmer N.D., Hicks P.J., Sale M.M., Langefeld C.D., Freedman B.I., Divers J., and Bowden D.W. Association analysis in African Americans of European-derived type 2 diabetes single nucleotide polymorphisms from whole-genome association studies. Diabetes 57 (2008) 2220-2225
36. Maddux B.A., Sbraccia P., Kumakura S., Sasson S., Youngren J., Fisher A., Spencer S., Grupe A., Henzel W., and Stewart T.A. Membrane glycoprotein PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus. Nature 373 (1995) 448-451
37. Meigs J.B., Manning A.K., Fox C.S., Florez J.C., Liu C., Cupples L.A., and Dupuis J. Genome-wide association with diabetes-related traits in the Framingham Heart Study. BMC Med. Genet. 8 Suppl 1 (2007) S16
38. Meyer J.M. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J. Clin. Psychiatry 63 (2002) 425-433
39. Miyake K., Horikawa Y., Hara K., Yasuda K., Osawa H., Furuta H., Hirota Y., Yamagata K., Hinokio Y., Oka Y., Iwasaki N., Iwamoto Y., Yamada Y., Seino Y., Maegawa H., Kashiwagi A., Yamamoto K., Tokunaga K., Takeda J., Makino H., Nanjo K., Kadowaki T., and Kasuga M. Association of TCF7L2 polymorphisms with susceptibility to type 2 diabetes in 4, 087 Japanese subjects. J. Hum. Genet. 53 (2008) 174-180
40. Morrison J.A., Gruppo R., Glueck C.J., Stroop D., Fontaine R.N., Wang P., and Smith K.L. Population-specific alleles: the polymorphism (K121Q) of the human glycoprotein PC-1 gene is strongly associated with race but not with insulin resistance in black and white children. Metabolism 53 (2004) 465-468
41. Muoio D.M., and Newgard C.B. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat. Rev. Mol. Cell Biol. 9 (2008) 193-205
42. Nelson W.J., and Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303 (2004) 1483-1487
43. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 19 Suppl 1 (2005) 1-93
44. Nurnberger Jr. J.I., Blehar M.C., Kaufmann C.A., York-Cooler C., Simpson S.G., Harkavy-Friedman J., Severe J.B., Malaspina D., and Reich T. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch. Gen. Psychiatry 51 (1994) 849-859
45. Pizzuti A., Frittitta L., Argiolas A., Baratta R., Goldfine I.D., Bozzali M., Ercolino T., Scarlato G., Iacoviello L., Vigneri R., Tassi V., and Trischitta V. A polymorphism (K121Q) of the human glycoprotein PC-1 gene coding region is strongly associated with insulin resistance. Diabetes 48 (1999) 1881-1884
46. Prunier C., Hocevar B.A., and Howe P.H. Wnt signaling: physiology and pathology. Growth Factors 22 (2004) 141-150
47. Rampersaud E., Damcott C.M., Fu M., Shen H., McArdle P., Shi X., Shelton J., Yin J., Chang Y.P., Ott S.H., Zhang L., Zhao Y., Mitchell B.D., O'Connell J., and Shuldiner A.R. Identification of novel candidate genes for type 2 diabetes from a genome-wide association scan in the Old Order Amish: evidence for replication from diabetes-related quantitative traits and from independent populations. Diabetes 56 (2007) 3053-3062
48. Rasmussen S.K., Urhammer S.A., Pizzuti A., Echwald S.M., Ekstrom C.T., Hansen L., Hansen T., Borch-Johnsen K., Frittitta L., Trischitta V., and Pedersen O. The K121Q variant of the human PC-1 gene is not associated with insulin resistance or type 2 diabetes among Danish Caucasians. Diabetes 49 (2000) 1608-1611
49. Ridderstrale M., Parikh H., and Groop L. Calpain 10 and type 2 diabetes: are we getting closer to an explanation?. Curr. Opin. Clin. Nutr. Metabol. Care 8 (2005) 361-366
50. Sale M.M., Smith S.G., Mychaleckyj J.C., Keene K.L., Langefeld C.D., Leak T.S., Hicks P.J., Bowden D.W., Rich S.S., and Freedman B.I. Variants of the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in an African-American population enriched for nephropathy. Diabetes 56 (2007) 2638-2642
51. Saxena R., Gianniny L., Burtt N.P., Lyssenko V., Giuducci C., Sjogren M., Florez J.C., Almgren P., Isomaa B., Orho-Melander M., Lindblad U., Daly M.J., Tuomi T., Hirschhorn J.N., Ardlie K.G., Groop L.C., and Altshuler D. Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes 55 (2006) 2890-2895
52. Saxena R., Voight B.F., Lyssenko V., Burtt N.P., de Bakker P.I., Chen H., Roix J.J., Kathiresan S., Hirschhorn J.N., Daly M.J., Hughes T.E., Groop L., Altshuler D., Almgren P., Florez J.C., Meyer J., Ardlie K., Bengtsson Bostrom K., Isomaa B., Lettre G., Lindblad U., Lyon H.N., Melander O., Newton-Cheh C., Nilsson P., Orho-Melander M., Rastam L., Speliotes E.K., Taskinen M.R., Tuomi T., Guiducci C., Berglund A., Carlson J., Gianniny L., Hackett R., Hall L., Holmkvist J., Laurila E., Sjogren M., Sterner M., Surti A., Svensson M., Svensson M., Tewhey R., Blumenstiel B., Parkin M., Defelice M., Barry R., Brodeur W., Camarata J., Chia N., Fava M., Gibbons J., Handsaker B., Healy C., Nguyen K., Gates C., Sougnez C., Gage D., Nizzari M., Gabriel S.B., Chirn G.W., Ma Q., Parikh H., Richardson D., Ricke D., and Purcell S. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316 (2007) 1331-1336
53. Scott L.J., Mohlke K.L., Bonnycastle L.L., Willer C.J., Li Y., Duren W.L., Erdos M.R., Stringham H.M., Chines P.S., Jackson A.U., Prokunina-Olsson L., Ding C.J., Swift A.J., Narisu N., Hu T., Pruim R., Xiao R., Li X.Y., Conneely K.N., Riebow N.L., Sprau A.G., Tong M., White P.P., Hetrick K.N., Barnhart M.W., Bark C.W., Goldstein J.L., Watkins L., Xiang F., Saramies J., Buchanan T.A., Watanabe R.M., Valle T.T., Kinnunen L., Abecasis G.R., Pugh E.W., Doheny K.F., Bergman R.N., Tuomilehto J., Collins F.S., and Boehnke M. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316 (2007) 1341-1345
54. Sladek R., Rocheleau G., Rung J., Dina C., Shen L., Serre D., Boutin P., Vincent D., Belisle A., Hadjadj S., Balkau B., Heude B., Charpentier G., Hudson T.J., Montpetit A., Pshezhetsky A.V., Prentki M., Posner B.I., Balding D.J., Meyre D., Polychronakos C., and Froguel P. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445 (2007) 881-885
55. Stadeli R., Hoffmans R., and Basler K. Transcription under the control of nuclear arm/beta-catenin. Curr. Biol. 16 (2006) R378-R385
56. Stahl S.M., Mignon L., and Meyer J.M. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?. Acta Psychiatr. Scand. 119 (2009) 171-179
57. Steinthorsdottir V., Thorleifsson G., Reynisdottir I., Benediktsson R., Jonsdottir T., Walters G.B., Styrkarsdottir U., Gretarsdottir S., Emilsson V., Ghosh S., Baker A., Snorradottir S., Bjarnason H., Ng M.C., Hansen T., Bagger Y., Wilensky R.L., Reilly M.P., Adeyemo A., Chen Y., Zhou J., Gudnason V., Chen G., Huang H., Lashley K., Doumatey A., So W.Y., Ma R.C., Andersen G., Borch-Johnsen K., Jorgensen T., Vliet-Ostaptchouk J.V., Hofker M.H., Wijmenga C., Christiansen C., Rader D.J., Rotimi C., Gurney M., Chan J.C., Pedersen O., Sigurdsson G., Gulcher J.R., Thorsteinsdottir U., Kong A., and Stefansson K. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat. Genet. 39 (2007) 770-775
58. Sutton L.P., Honardoust D., Mouyal J., Rajakumar N., and Rushlow W.J. Activation of the canonical Wnt pathway by the antipsychotics haloperidol and clozapine involves dishevelled-3. J. Neurochem. (2007)
59. Torrent C., Amann B., Sanchez-Moreno J., Colom F., Reinares M., Comes M., Rosa A.R., Scott J., and Vieta E. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr. Scand. 118 (2008) 4-18
60. Tschoner A., Engl J., Rettenbacher M., Edlinger M., Kaser S., Tatarczyk T., Effenberger M., Patsch J.R., Fleischhacker W.W., and Ebenbichler C.F. Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study. Pharmacopsychiatry 42 (2009) 29-34
61. Weedon M.N. The importance of TCF7L2. Diabet. Med. 24 (2007) 1062-1066
62. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
63. Willert K., and Jones K.A. Wnt signaling: is the party in the nucleus?. Genes Dev. 20 (2006) 1394-1404
64. Wirshing D.A., Boyd J.A., Meng L.R., Ballon J.S., Marder S.R., and Wirshing W.C. The effects of novel antipsychotics on glucose and lipid levels. J. Clin. Psychiatr. 63 (2002) 856-865
65. Wu Y., Li H., Loos R.J., Yu Z., Ye X., Chen L., Pan A., Hu F.B., and Lin X. Common variants in CDKAL1, CDKN2A/B, IGF2BP2, SLC30A8 and HHEX/IDE genes are associated with type 2 diabetes and impaired fasting glucose in a Chinese Han population. Diabetes (2008)
66. Yan Y., North K.E., Ballantyne C.M., Brancati F.L., Chambless L.E., Franceschini N., Heiss G., Kottgen A., Pankow J.S., Selvin E., West S.L., and Boerwinkle E. Transcription factor 7-like 2 (TCF7L2) polymorphism and context-specific risk of type 2 diabetes in African American and Caucasian adults: the atherosclerosis risk in communities study. Diabetes 58 (2009) 285-289
67. Zeger S.L., and Liang K.Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42 (1986) 121-130
68. Zeggini E., Weedon M.N., Lindgren C.M., Frayling T.M., Elliott K.S., Lango H., Timpson N.J., Perry J.R., Rayner N.W., Freathy R.M., Barrett J.C., Shields B., Morris A.P., Ellard S., Groves C.J., Harries L.W., Marchini J.L., Owen K.R., Knight B., Cardon L.R., Walker M., Hitman G.A., Morris A.D., Doney A.S., McCarthy M.I., and Hattersley A.T. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316 (2007) 1336-1341